Brain Cancer
Servier to Seek FDA, EMA Approvals for Vorasidenib in IDH-Mutant Glioma
The firm plans to submit data from the Phase III INDIGO study to regulators in the US and Europe by the end of 2023 and in early 2024, respectively.
The firm hopes to establish a role for cancer vaccines as a tumor shrinking therapy, not just a tumor preventing therapy.
Cantex Pharmaceuticals Launches Phase II Trial of Azeliragon in Unmethylated Glioblastoma
The first newly diagnosed glioblastoma patient has been enrolled in the clinical trial of Cantex's RAGE inhibitor azeliragon plus radiation therapy at the Lenox Hill Hospital.
Day One Completes NDA Submission for Tovorafenib in Childhood Brain Cancer
In updated clinical results included in the submission, the overall response rate was 67 percent and 93 percent of patients experienced some clinical benefit.
Biocept Licenses CNSide Liquid Biopsy Assay to Plus Therapeutics
Under the agreement, Plus is using the cerebrospinal fluid cell-based assay in its ongoing clinical trial of the radiotherapeutic rhenium 186 obisbemeda.